Background: The diagnosis of tumour progression or progressive disease (PD) is a key element for designing and interpreting contemporary phase II trials. In some cases, PD is stated by the physician and is not formally confirmed by imaging.
Introduction
Phase II trials are designed to sort out drugs with disappointing level of activity. The decision rules and sample size calculation of phase II trials are basically based on the following parameters: P0 (an inacceptable level of activity, ''failure rate''), P1 (a desirable level of activity, ''success rate'') and the couple a/b [1] . At the end, the primary endpoint is used as a binary parameter that partitions patients into two categories: responders (success) and nonresponders (failure).
Regardless of the method used for assessing the activity of new drugs or new regimens in phase II trials (objective response rates [2, 3] , non-progression rate at fixed time points [4] , growth modulation index [5] , etc.) tumour progression (or progressive disease, PD) is a key element for defining success or failure. As per protocol and to the extent possible, investigators should document tumour progression by imaging. This assessment, however, is not possible in some circumstances: rapid deterioration of the patient's general condition, contraindication of imaging, refusal of a new examination, patient withdrawal of informed consent … These circumstances are taken into account in guidelines defining PD in clinical trial, such as RECIST [2] . RECIST integrates clinical judgement of PD, when imaging is not feasible or possible [2] . Nevertheless, in case of clinical judgment of PD without confirmation by imaging, there are doubts concerning the robustness and reliability of this information. Is the clinical judgment of PD really predictive of progression subsequently proven by imaging? Furthermore, is there an overestimation of PD occurrence by physicians? Finally, do severe toxicities altering the patient general conditions mimic PD? We have reviewed all consecutive medical records of patients treated in phase II trials in our institution in order to explore the predictive value of clinical judgment of PD.
Patients and Methods

General methodology
An independent investigator (NK) reviewed the medical records of all consecutive patients enrolled in phase II trials investigating systemic treatment for advanced solid tumours between January 2008 and November 2010. The data collected were (i) tumour and patient characteristics at baseline, (ii) the nature of investigational agents or combinations, (iii) tumour status at the last assessment, (iv) clinical judgment of progression and (v) results of planned tumour imaging.
Diagnostic accuracy of the clinical judgment of PD was examined as a diagnostic test in comparison to PD diagnosed by imaging according to RECIST [2] . We constructed a classical 262 table in order to calculate sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) and accuracy (the rate of well-classified patients). Comparisons between the different categories of patients were conducted using the Fischer exact test and the Mann-Whitney test. Survival curves were constructed using the Kaplan-Meier method and comparisons were carried out with the log rank test.
Ethics
The internal ethic board of our institution (Clinical Trial Commission; ''Commission interne des études cliniques'') had approved this study. According to the French laws (law of the 06th January 1978 about data, data-collection and freedom, in case of single-centre, retrospective study based on already recorded and stored data, there is no need of specific written informed consent; but all patients have been orally informed about the potential use of their collected data for future research. We have obtained the agreement Nu 1034071 from the ''National Commission about Data-collection and Freedom'' (''Commission Nationale Informatique et Liberté'').
Results
General
129 patients were included in 32 different phase II trials between January 2008 and November 2010. Until now, 84 (65%) patients discontinued the investigational treatment for PD; 27 discontinued the trial treatment for reasons other than PD: investigator's decision (2 cases), severe toxicities (13 cases), consent withdrawal (3 cases), death from other cause (2 cases) and study termination (7 cases).18 patients are still currently treated in these phase II trials. Patient characteristics are listed in Table 1 .
Description of tumour progressions
Eighty-four patients experienced PD with the trial treatment, among whom 47 PD were documented by planned imaging without clinical signs suggestive of tumour progression (Figure 1) . One patient experienced ''biological progression'' without radiological confirmation (ovarian cancer patient with increasing CA125; this patient was excluded from subsequent analysis). ''Clinical judgment of PD'' was pronounced for 36 patients, among whom imaging was not available in 7 cases (withdrawal of informed consent (3 cases), death in the very next days (3 cases) or severe deterioration of general condition (1 case). Imaging was available in the other 29 cases and PD was confirmed in 28 of them (Table 2) .
Diagnostic accuracy of clinical judgment of progression
The PPV of clinical judgment of PD was very high (96%). In other words, when physicians suspected tumour progression, it was confirmed by subsequent imaging in the vast majority of cases. The specificity of clinical judgment was also high (94%), meaning that radiological examination rejected only very few clinical judgments of PD. On the contrary and as expected, because most of PD are asymptomatic, the Se and NPV were low, at 37% and 27% (Table 2 ).
Factors associated with clinical judgment of tumour progression
The sole clinical factor different among patients with clinical judgment of PD and those with PD diagnosed by planned tumour assessment was the deterioration of general patient status ( Table 3) . The median time to PD was 118 days for patients with progression diagnosed by planned imaging, 102 days for patients with clinical judgment of PD confirmed by subsequent imaging, and 28 days for patients with clinical judgment of PD without imaging confirmation (p,0.0001). This suggests that physicians reach an early diagnosis of symptomatic forms of PD and then anticipate tumour assessment. The overall survival of patients with clinical judgment of PD without radiological documentation was worse than that of patients with radiological documentation of PD (p,0.05) (Figure 2) . Moreover, at the time of PD, maximal haematological and non-haematological toxicities were similar in patients with clinical judgment of PD, whether or not radiological documentation was available (Table 3 ). This suggests that treatment-related toxicities did not mimic PD.
Limitations
There are several limitations related to the retrospective and single-centre nature of this study. For example, in seven cases of patients with clinical judgment of PD, a formal radiological tumour assessment was unavailable, thereby constituting a bias, although a sensitivity analysis had been conducted. In the bestcase scenario (these 7 patients actually had PD), the PPV was 35/ 36 (97%). In the worst-case scenario (none actually had tumour progression), the PPV was 77%. The second limitation of this study is the time biais. The median time to progression appeared longer in cases of progression diagnosed by imaging compared to progression diagnosed by clinical judgment. Nevertheless, in case of clinically suspected PD the physicians anticipated the imaging assessment. This shortened the time to progression.
Conclusions
Definition of PD is a key-element of the design of current phase II trials. Moreover, time to progression or progression-free survival often replace overall survival in contemporary phase III trials. Time to progression and progression-free survival are partly subjective or subject to bias (measurement error in imaging analysis, non radiographic worsening of the clinical state, impact of other causes of treatment discontinuation…) [6] [7] . Regarding these problems, we attempt to estimate the risk of overestimate the occurrence of tumour progression by the clinical judgment. 
